Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy (Q44659411)

5 December 2017

title

Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy (English)

1 reference

5 December 2017

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

3 April 2024

author name string

Ian E. Smith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623523

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623523

3 April 2024

publication date

1 September 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S0960076003003698?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

https://api.elsevier.com/content/article/PII:S0960076003003698?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

5 December 2017

volume

86

1 reference

5 December 2017

issue

3-5

1 reference

5 December 2017

page(s)

289-293

1 reference

Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

1 reference

7 January 2021

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900369-8

7 January 2021

Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer

4

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00369-8

3 April 2024

Identifiers

1 reference

release_winybyseqvfurabsmyc7e3hena

5 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/winybyseqvfurabsmyc7e3hena

24 November 2022

mapped directly with Wikidata item

1 reference